Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy.
• CD123-targeted therapies represent a significant advancement, offering the first generation of specific treatments.
• Despite progress, challenges remain, including disease relapse, central nervous system (CNS) involvement, and limited global accessibility of targeted agents, indicating substantial unmet medical needs.

Purpose of the Study:

• To review emerging clinical concepts and special considerations in BPDCN management.
• To discuss novel markers, the role of TET2 mutations, and co-occurring hematologic malignancies.
• To highlight CNS involvement, evolving therapeutic strategies, and future directions in BPDCN treatment.

Main Methods:

• Literature review of recent clinical developments in BPDCN.
• Analysis of emerging diagnostic markers and prognostic factors.
• Examination of current and investigational therapeutic approaches, including targeted therapies and combination treatments.

Main Results:

• Identification of novel markers for distinguishing BPDCN from related entities.
• Elucidation of the role of TET2 mutations and the frequency of prior/concomitant hematologic malignancies.
• Increased recognition of CNS involvement and strategies for its prevention and treatment.

Conclusions:

• The BPDCN field is rapidly evolving, with CD123-targeted therapies offering initial clinical benefits.
• Addressing relapse, CNS disease, and accessibility are critical for improving patient outcomes.
• Future research focuses on combination therapies and next-generation CD123-targeted agents to overcome current limitations.